Results 61 to 70 of about 195,479 (250)

Lipid Nanoparticle Co‐Delivery of mRNA and a Small Molecule Drug for Oral Cancer Chemoimmunotherapy

Advanced Materials, EarlyView.
Co‐encapsulation of p53 mRNA and the small molecule ciclopirox within a lipid nanoparticle yields an all‐in‐one chemoimmunotherapy for oral squamous cell carcinoma. The platform engages caspase‐driven apoptosis in cancer cells while repolarizing tumor‐associated macrophages, achieving tumor reduction in both p53‐susceptible and p53‐resistant models and
Marshall S. Padilla, Jacqueline J. Li, Qunzhou Zhang, Korey Patwari, Shihong Shi, Hannah M. Yamagata, Ryann A. Joseph, Briyanna N. Hymms, Sridatta V. Teerdhala, Emily Fitzgerald, Ori Z. Chalom, Kushol Gupta, Mohamad‐Gabriel Alameh, Drew Weissman, Anh D. Le, Michael J. Mitchell   +15 more
wiley   +1 more source

Navigating Lipid Nanostructure Design Space Through Continuous Microfluidic Automation

Advanced Materials, EarlyView.
LipidXplorer is a novel microfluidic platform which enables rapid navigation of lipid particle design space for high‐resolution phase mapping, lipid nanoparticle optimization, membrane biophysics, and functional nanomaterial discovery. It combines programmable composition control, continuous nanoparticle formation, and automated well‐plate collection ...
Bradley Diggines, Marcus Fletcher, Manuel Bibrowski, Karnyart Samnuan, Rongjun Chen, David J. Peeler, Amjad Abouselo, Morag R. Hunter, Molly M. Stevens, Nicholas J. Brooks, Yuval Elani   +10 more
wiley   +1 more source

A Chemical Framework for Engineering Extracellular Vesicles’ Biointerface to Advance Precision Therapeutics

Advanced Materials, EarlyView.
Extracellular vesicles (EVs) are cell‐derived nanoparticles that mediate intercellular communication through their dynamic biointerfaces. Owing to their intrinsic biological functions, EVs have emerged as promising platforms for biomedical applications.
Leila Pourtalebi Jahromi, Felix Geng, Jan‐Noël Frenzke, Gregor Fuhrmann   +3 more
wiley   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

In vitro and in vivo efficacy of a Rift Valley fever virus vaccine based on pseudovirus

Human Vaccines & Immunotherapeutics, 2019
Rift Valley fever virus (RVFV), a recognized category A priority pathogen, causes large outbreaks of Rift Valley fever with some fatalities in humans in humans and huge economic losses in livestock.
Jian Ma, Ruifeng Chen, Weijin Huang, Jianhui Nie, Qiang Liu, Youchun Wang, Xiaoming Yang   +6 more
doaj   +1 more source

Radiotherapy Enhances the Oncolytic Efficacy of the Novel Oncolytic Herpesvirus VG161 and Amplifies Its Antitumor Immunity in Breast Cancer

Advanced Science, EarlyView.
RT promotes VG161 replication in BC and its immunostimulatory transgenes expression, which is mediated by the upregulation of GADD34 and HVEM caused by RT. The combination therapy with VG161 and RT increases the abundances of tumor‐infiltrating lymphocytes and elicits potent systemic antitumor immunity, thereby effectively inhibiting local tumors and ...
Lijuan Lyu, Ming Yi, Ji Chen, Zeda Zhao, Ruocen Liao, Yingnan Wang, Shengtao Hu, Jun Ding, Ronghua Zhao, William Jia, Yinan Shen, Yongchang Wei, Kongming Wu, Zhijun Dai   +13 more
wiley   +1 more source

Nanomaterial for Adjuvants Vaccine: Practical Applications and Prospects

Indonesian Journal of Chemistry
Vaccines contain adjuvants to strengthen the immune responses of the receiver against pathogen infection or malignancy. A new generation of adjuvants is being developed to give more robust antigen-specific responses, specific types of immune responses ...
Vy Anh Tran, Vien Vo, Vinh Quang Dang, Giang Ngoc Linh Vo, Ta Ngoc Don, Van Dat Doan, Van Thuan Le   +6 more
doaj   +1 more source

Development of a Tuberculosis Vaccine Seed: Construction of Resuscitation-Promoting Factor B DNA Vaccine and its Expression in Vitro and in Vivo

Makara Journal of Health Research, 2018
Background: Tuberculosis (TB) is a chronic infection disease caused by Mycobacterium tuberculosis (Mtb) and has a high death-rate worldwide. Bacillus Calmette-Guerin is the only TB vaccine which is currently available with several drawbacks, such as its ...
Ratih D. Saraswati, Andriansjah Rukmana, Fithriyah, Aprilia Rakhmawati   +3 more
doaj   +1 more source

Cysteine Redox State Governs the Condensation Pathway of Hendra Virus W Protein and Differentially Impacts Type I IFN and NF‐κB Signaling

Advanced Science, EarlyView.
The cysteine redox state of the Hendra virus W (WHeV) protein controls assembly into fibrils or amorphous aggregates, with residues 2–29 required for fibrillation. In cells, WHeV forms different types of nuclear condensates. Impaired ability to form redox‐sensitive, non‐filamentous condensates reduces WHeV inhibition of the NF‐κB pathway, while it ...
Frank Gondelaud, Alexandre Lalande, Giulia Pesce, Auriane Bouchet, Carole Meunier, Christophe Bignon, Denis Ptchelkine, Yu Gu, Eva Ogire, Pierre‐Yves Lozach, Denis Gerlier, Cyrille Mathieu, Sonia Longhi   +12 more
wiley   +1 more source

Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma

Human Vaccines & Immunotherapeutics, 2017
We report on the design of a phase I, non-randomized, open-label study of idiotypic DNA vaccination in patients with B-cell non-Hodgkin's lymphoma (ISRCTN31090206).
A. N. Meleshko, N. A. Petrovskaya, N. Savelyeva, K. P. Vashkevich, S. N. Doronina, N. V. Sachivko   +5 more
doaj   +1 more source